Manuka Inc. (MNKA)

[meltup]

ICTSF owns some ATMS?....

[midastouch017]

Artemis Therapeutics (ATMS)
0.228 ^ 0.192 (533.33%)
Volume: 20,986 @08/25/20 11:20:35 AM EDT

[pray]

Price Was Double When Cully Started ...

Looks like he will drive it down to trips before RS as he did 6 times with anx.

Has never had 1 successful test ... guy worthless.

[funnyG986]

ATMS patent news today. 0.7x0.95

[funnyG986]

ATMS company presentation updated 09/12/2017 showing phase II trial on going.

[funnyG986]

ATMS shows news on their website; they attended Rodman & Renshaw Investment Conference in September. Today's filing showing new institutional owner Michael Vasinkevich (Acumen) 13%
https://www.otcmarkets.com/financialReportViewer?symbol=ATMS&id=180565

If you google Michael Vasinkevich, you will find that he is the founding partner of Rodman & Renshaw Capital Group. News all pointing to Rodman & Renshaw Investment. Coincidence ?

Mr. Michael Vasinkevich serves as Senior Managing Director, Vice Chairman and Founding Partner of Rodman & Renshaw Capital Group, Inc., and served as its Senior Managing Director since July 2002.

Artemis Presentation Webcast – Rodman & Renshaw 19th Annual Global Investment Conference
Brian M. Culley, CEO of Artemis Therapeutics Inc. (OTCMKTS: ATMS), presents on the company at the Rodman & Renshaw 19th Annual Global Investor Conference.

Click here to view the webcast
Post navigation
http://www.artemis-therapeutics.com/2017/09/12/artemis-presentation-webcast-rodman-renshaw-19th-annual-global-investment-conference/

[funnyG986]

ATMS from today's OTCQB certificate. NEW OWNERSHIP from ACUMEN 13%

Acumen was incorporated on April 1, 2001, with seed capital from the Rockefeller Foundation, Cisco Systems Foundation and three individual philanthropists. Acumen’s investors and advisors include also the Bill & Melinda Gates Foundation, Google.org and the Skoll Foundation.[4] Jacqueline Novogratz is the founder and CEO of Acumen.[5] In 2016, Jacqueline received the Forbes Lifetime Achievement Award for her work in social entrepreneurship.
In 2015, Acumen was named one of Fast Company’s Top 10 Most Innovative Not-for-Profit Companies. Learn more at www.acumen.org and on Twitter @Acumen.


Name Address (City and State only) % Shares Owned
Acumen 13%
Tonak Ltd Israel 52%
Zavit Ltd Israel 7%
Officers:
Brian Culley Encinitas, California 0%
Chanan Morris Israel 0%
Dana Wolf Israel 1%
OTC Markets Group Inc. April 17, 2017

Directors:
Gadi Peleg New York 0%
Israel Alfassi Israel 5%

[pray]

High profile you are right. Guy had seven major drugs at MAST and botched every test. Had 2 reverse splits, quadrupled share counted and diluted a $8.00 stock to .15 cents before the third RS.

[funnyG986]

ATMS 8k today new CEO Brian Culley was the CEO for Mast Therapeutics, Inc. (NYSE MKT: MSTX) and he sold company to NASDAQ:SVRA in April 2017

On August 9, 2017, the Board of Directors (the “Board”) of the Company appointed Brian Culley as Interim Chief Executive Officer.

Brian Culley, 46, served as Mast Therapeutics, Inc.’s (“Mast”) Chief Executive Officer since February 2010 and member of its Board of Directors since December 2011, until Mast’s merger with Savara, Inc. (SVRA) in April 2017. Mr. Culley served from January 2007 to February 2010 as Mast’s Chief Business Officer and Senior Vice President, from February 2006 to January 2007 as Mast’s Senior Vice President, Business Development, and from December 2004 to February 2006 as Mast’s Vice President, Business Development. From 2002 until 2004, Mr. Culley was Director of Business Development and Marketing for Immusol, Inc. From 1999 until 2000, he worked at the University of California, San Diego (UCSD) department of technology transfer & intellectual property services and from 1996 to 1999 he conducted drug development research for Neurocrine Biosciences, Inc. Mr. Culley has 25 years of business and scientific experience in the life science industry. He received a B.S. in biology from Boston College, a masters in biochemistry and molecular biology from the University of California, Santa Barbara, and an M.B.A. from The Johnson School of Business at Cornell University.

In connection with Mr. Culley’s appointment, the Company entered into an employment agreement with Mr. Culley, dated August 9, 2017 (the “Culley Employment Agreement”). Pursuant to the Culley Employment Agreement, the Company agreed to pay him an annual base salary of $150,000. In addition, if the Company receives a capital investment in an aggregate amount that exceeds $2 million (a “Capital Raise”) by December 31, 2017, Mr. Culley’s annual base salary will be increased to $300,000. The Culley Employment Agreement further provides that Mr. Culley will be entitled to an annual bonus equal to up to 50% of the annual base salary, up to a maximum of $120,000 in the aggregate, subject to certain performance goals to be determined by the Board. In addition, in the event of a successful Capital Raise prior to December 31, 2017, Mr. Culley will also be eligible to receive a one time bonus of $12,500 for each month he is employed by the Company prior to the date of such investment.

Also, in connection with Mr. Culley’s appointment, the Company agreed to issue Mr. Culley a non-statutory stock option to purchase 242,640 shares of the Company’s common stock, with an exercise price of $1.30 per share, with such option subject to a pro rata 48 month vesting period. In the event Mr. Culley’s employment is terminated without cause within 60 days of a change of control (as defined in the Culley Employment Agreement) then 50% of such outstanding and unvested options shall become immediately vested, and if Mr. Culley’s employment is terminated for good reason within 60 days of a change of control (as defined in the Culley Employment Agreement), then 100% of such outstanding and unvested options shall become immediately vested. In addition, subject to the approval of the Board, Mr. Culley may be entitled to receive an additional, one time, fully vested non-statutory stock option grant to purchase up to 48,528 shares of the Company’s common stock.

Pursuant to the Culley Employment Agreement, either the Company or Mr. Culley may terminate the Culley Employment Agreement upon sixty days notice, provided, however that the Company may terminate the Culley Employment Agreement immediately for cause.

There are no transactions in which Mr. Culley has an interest requiring disclosure under Item 404(a) of Regulation S-K.

The description of the Culley Employment Agreement is qualified in its entirety by reference to the complete text of the Culley Employment Agreement which has been filed with this Current Report on Form 8-K as Exhibit 10.1.


link
http://www.prnewswire.com/news-releases/savara-announces-closing-of-merger-with-mast-therapeutics-300447355.html

[funnyG986]

ATMS another filing today.

[funnyG986]

ATMS somehow I missed this PR

Prof. Dana Wolf, M.D., to Present at CMV2017: 6th International Congenital CMV Conference and 16th International CMV/Betaherpesvirus Workshop

http://www.artemis-therapeutics.com/category/press-releases/

[funnyG986]

ATMS very nice 8k investor presentation today. must read! Super strong management team!

8k
http://ih.advfn.com/p.php?pid=nmona&article=74620467&symbol=ATMS

Investor Presentation
https://www.sec.gov/Archives/edgar/data/1062128/000117891317001503/exhibit_99-1.htm

[funnyG986]

Reverse merger to get public

[jamesbarton1]

funnyG, any idea why they bought Inksure?

[funnyG986]

Very high profile CEO and major institutional shareholders

[jamesbarton1]

You could drive a truck through the bid/ask spread.

[jamesbarton1]

Odd. Ameritrade and Yahoo show it as 1.1M. Nonetheless, it's not a huge amount to move the stock that much. FunnyG posted what appear to be both reasons for the big move: patent filing coupled with a very small float.

[funnyG986]

ATMS 81% OS held by insiders. 60% held by Mr. Nadav Kidron who is the CEO of ORMP (NASDAQ)

Shareholder (1)

Beneficial Ownership

Israel Alfassi 253,460 5.26%
Gadi Peleg 69,556 1.44%
Dana Wolf 35,203

Officers and Directors as a group (5 persons) 358,219 6.70%

Other 5% Holders 243,588 5.06%
Tonak Ltd. 2,880,568 (4) 59.78%

Zavit Holdings Ltd. 337,947 7.01%
ICTS International N.V. and affiliates 198,311 4.12%

(4)
Consists of 2,880,568 shares of common stock beneficially owned by Tonak Ltd. Mr. Nadav Kidron is the natural person with voting and dispositive power over our securities held by Tonak Ltd.

[funnyG986]

ATMS something from today's filing; Patents!

As part of our License Agreement, we have obtained a license relating to a family of patent applications derived from a single Patent Cooperation Treaty application filed on April 17, 2013. Specifically, U.S. patent application No. 14/394,973, which is jointly assigned to Hadasit and RDC, has been licensed to us. The claims of this patent application that were deemed allowable are directed to methods of treating a herpes viral infection or suppressing herpes viral replication (method of use claims). Additionally, a continuation application of U.S. patent serial No. 15/361150 was filed on November 25, 2016 with claims directed specifically to methods of treatment of HCMV. This patent will be due to expire on April 17, 2033. Importantly, there are pending counterpart patent applications in Europe and Japan.

[midastouch017]

You got it wrong.
Volume was 1.5K

Artemis Therapeutics (ATMS)
1.5 ^ 0.85 (130.77%)

[jamesbarton1]

Any thoughts on today's action? +130% on 1.1M shares. The volume wasn't that impressive, but the price action was.

[funnyG986]

Nice news. Nasdaq Executive as CEO is the start of something huge

[midastouch017]

Change in Directors or Principal Officers, Financial Statements and Ex


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Appointment of Chief Executive Officer

New York Global Innovations Inc., or the Company, has appointed Mr. Peter N. Payne, age 57, to serve as the Company's Chief Executive Officer, effective as of January 10, 2017.

For his services as Chief Executive Officer, Mr. Payne will receive an annual salary in the amount of $180,000. If, by December 31, 2017 (the "Investment Date"), the Company receives capital investments in the aggregate amount of at least $4,000,000, Mr. Payne's salary will increase to an annual rate of $300,000, and he shall receive a bonus of $10,000 for each month of employment prior to the Investment Date. Mr. Payne is also entitled to receive an annual bonus at the discretion of the Company's Board of Directors.

Mr. Payne was previously employed as founder and President of Gennaker Bio, LLC, a life sciences consulting firm, since January 2016, where he also served in the same capacity from July 2012 to October 2013. From November 2014 to January 2016, he served as Senior Vice President of Business Development & Corporate Strategy at Chimerix, Inc. (NASDAQ: CMRX). Prior to his time at Chimerix, Inc., starting in October 2013, Mr. Payne was Chief Executive Officer and Co-Founder of eXcelerate Research, Inc. From January 2011 to June 2012, Mr. Payne was employed as the Chief Business Officer and head of U.S. Operations for TcLand Expression, S.A.

There are no transactions in which Mr. Payne has an interest requiring disclosure under Item 404(a) of Regulation S-K.

The employment agreement, dated as of January 5, 2017 and entered into as of January 10, 2017, by and between the Company and Mr. Payne (the "Employment Agreement"), is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein. The foregoing is only a description of the material terms of the Employment Agreement and does not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by reference to such exhibit.

[Renee]

INKSD changed to ATMS:

http://otce.finra.org/DLSymbolNameChanges

[get going]

You never know after a reverse split.

[wz9ytp]

Best of luck to all holding here

[Renee]

INKS: effective Dec. 20,2016 New York Global Innovations Inc. will change to Artemis Therapeutics Inc. and a one for 50 reverse split:

http://otce.finra.org/DLSymbolNameChanges

[get going]

Looking good today...can we keep it going?

[Talc Moan]

Nice Move! $INKS

[get going]

Best outcome possible.

[funnyG986]

the prefer series B shares are all converted to common now, which is issued for the reverse merger. there is no dilution on this one.

[get going]

Your right...no rush to the exits.

[funnyG986]

and no one is selling lol

[get going]

I'm surprised as well.

[funnyG986]

INKS AS reduction and 1-50 RS. Serial B shares also converted to common at the rate with 1-50 in consideration.

Still planned RS, which surprised me.

Plan to load @0.01 level

[Renee]

InkSure Technologies Inc. changed to New York Global Innovations Inc.

http://otce.finra.org/DLSymbolNameChanges

[get going]

Good news, thanks.

[funnyG986]

INKS name change today to New York Global Innovations Inc. no RS
http://otce.finra.org/DLSymbolNameChanges

[get going]

INKS has been on a steady rise since the end of April, when it closed at .008. Closed today at .025 for over 300% increase from April. Imagine what will happen if we get some decent volume.

[get going]

Slowly moving forward.

[get going]

Sure moves nicely when we get some buying.

[wz9ytp]

What a difference a day makes!!!! 0 volume!

[funnyG986]

INKS is a strong reverse merger play. $0.03 break soon imo

[get going]

That's what I'm thinking as well.

[get going]

Looking much better today...volume sure makes a difference.

[Trades Mcgrady]

$INKS Looks like word is starting to get around a little

[get going]

Nice volume today...certainly heading in the right direction.

[funnyG986]

INKS 0.022 52w high. link back to my DD; Nasdaq Co Oramed Pharmaceuticals President owns 25% of the OS
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=124887206

[get going]

Looking good today...got some volume and moving forward.

[funnyG986]

INKS 0.016 X 0.02 now. blue sky after 0.02